JP2013509391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509391A5 JP2013509391A5 JP2012535956A JP2012535956A JP2013509391A5 JP 2013509391 A5 JP2013509391 A5 JP 2013509391A5 JP 2012535956 A JP2012535956 A JP 2012535956A JP 2012535956 A JP2012535956 A JP 2012535956A JP 2013509391 A5 JP2013509391 A5 JP 2013509391A5
- Authority
- JP
- Japan
- Prior art keywords
- provides
- crystalline
- inden
- oxoethyl
- methylpropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2,3-dihydro-1H-inden-2-yl Chemical group 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 2
- UWHCWRQFNKUYCG-QUZACWSFSA-N Epelsiban Chemical compound O=C([C@H](N1[C@@H](C(N[C@@H](C1=O)C1CC2=CC=CC=C2C1)=O)[C@@H](C)CC)C=1C(=NC(C)=CC=1)C)N1CCOCC1 UWHCWRQFNKUYCG-QUZACWSFSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25659409P | 2009-10-30 | 2009-10-30 | |
| US61/256,594 | 2009-10-30 | ||
| PCT/IB2010/003221 WO2011051814A1 (en) | 2009-10-30 | 2010-10-28 | Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000972A Division JP2016106102A (ja) | 2009-10-30 | 2016-01-06 | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013509391A JP2013509391A (ja) | 2013-03-14 |
| JP2013509391A5 true JP2013509391A5 (https=) | 2013-12-12 |
Family
ID=43921420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535956A Pending JP2013509391A (ja) | 2009-10-30 | 2010-10-28 | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 |
| JP2016000972A Pending JP2016106102A (ja) | 2009-10-30 | 2016-01-06 | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000972A Pending JP2016106102A (ja) | 2009-10-30 | 2016-01-06 | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8716286B2 (https=) |
| EP (1) | EP2493874A1 (https=) |
| JP (2) | JP2013509391A (https=) |
| WO (1) | WO2011051814A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3417851T3 (pl) | 2013-09-09 | 2020-12-14 | Peloton Therapeutics, Inc. | Etery arylowe i ich zastosowanie |
| US9884843B2 (en) | 2013-12-16 | 2018-02-06 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
| WO2016145236A1 (en) * | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Hif-2-alpha inhibitor polymorphs |
| WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| KR102001750B1 (ko) * | 2015-06-15 | 2019-07-18 | 밧세루 가가쿠 가부시키가이샤 | 해중 부착 생물 기피 조성물 |
| CA3009576A1 (en) | 2016-01-04 | 2017-07-13 | Merck Serono S.A. | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| UA127283C2 (uk) | 2016-07-21 | 2023-07-12 | Обсева С.А. | Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню |
| US20220323410A1 (en) | 2019-09-03 | 2022-10-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| WO2021160597A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596819A (en) | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
| DE3830096A1 (de) | 1988-09-03 | 1990-03-15 | Hoechst Ag | Piperazindione mit psychotroper wirkung |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5817751A (en) | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
| GB2326639A (en) | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
| TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| DE69940191D1 (de) | 1998-01-29 | 2009-02-12 | Aventis Pharma Inc | VERFAHREN ZUR HERSTELLUNG EINER N-i(ALIPHATHISCH ODER AROMATISCH)CARBONYL -2-AMINOACETAMID-VERBINDUNG UND EINER CYCLISCHEN VERBINDUNG |
| WO1999047549A1 (en) | 1998-03-16 | 1999-09-23 | Ontogen Corporation | PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0314733D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| GB0414100D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414092D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
-
2010
- 2010-10-28 JP JP2012535956A patent/JP2013509391A/ja active Pending
- 2010-10-28 WO PCT/IB2010/003221 patent/WO2011051814A1/en not_active Ceased
- 2010-10-28 US US13/504,681 patent/US8716286B2/en not_active Expired - Fee Related
- 2010-10-28 EP EP10807364A patent/EP2493874A1/en not_active Withdrawn
-
2014
- 2014-03-18 US US14/217,938 patent/US8815856B2/en not_active Expired - Fee Related
-
2016
- 2016-01-06 JP JP2016000972A patent/JP2016106102A/ja active Pending